OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

Conjunctival staining and ocular pain represent potential co-primary endpoints to be explored in future trials "The data from this first in-human trial of OK-101 in patients with DED have established a clear road map for future clinical development in this indication," said Gary S. Jacob, Ph.D., CEO of OKYO Pharma. "Through our analytical work we have concluded that conjunctival staining and ocular pain represent important and derisked endpoints to be studied further to help underserved patients whose dry e ...